Relevant bibliographies by topics / Oropharyngeal Cancers

Academic literature on the topic 'Oropharyngeal Cancers'

Author: Grafiati
Published: 10 December 2022
Last updated: 28 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Oropharyngeal Cancers.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Journal articles on the topic "Oropharyngeal Cancers":

1

Chan, Man Hin, Feng Wang, Wai kong Mang, and Lap Ah Tse. "Sex Differences in Time Trends on Incidence Rates of Oropharyngeal and Oral Cavity Cancers in Hong Kong." Annals of Otology, Rhinology & Laryngology 127, no. 12 (September 29, 2018): 895–902. http://dx.doi.org/10.1177/0003489418802287.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
Objectives: Worldwide studies have shown an increasing trend of oropharyngeal squamous cell carcinoma (OPSCC) but a decreasing trend of oral cavity cancers over the past 2 decades, particularly in developed countries with successful tobacco control. This trend has been attributed to the increase in the incidence of human papillomavirus (HPV)–associated OPSCC. The aim of this study was to examine sex differences in incidence trends of oropharyngeal and oral cavity cancers in Hong Kong from 1983 to 2014. Methods: Using data from the Hong Kong Cancer Registry from 1983 to 2014, age-standardized incidence rates for potentially HPV-associated sites (oropharyngeal) and non-HPV-associated sites (oral cavity) were calculated, stratified by sex and age groups. Joinpoint regression and an age-period-cohort model were used to assess incidence trends. Results: A total of 1,972 cases of oropharyngeal cancer and 7,389 cases of oral cavity cancer were diagnosed from 1983 to 2014. The male/female ratios were 4.16:1 for oropharyngeal cancers and 1.63:1 for oral cavity cancers. A significant increasing trend was observed in oropharyngeal cancers from 1994 to 2014 (average annual percentage change = 2.66, P < .05). In contrast, a significant decreasing trend was observed in oral cavity cancers from 1983 to 1994 (average annual percentage change = −5.36, P < .05). The trends were more significant in men and in patients aged 45 to 69 years. A positive birth cohort effect was observed for oropharyngeal cancer in men. Conclusions: The rising trend of oropharyngeal cancer and decreasing trend of oral cavity cancer in Hong Kong from 1983 to 2014 are consistent with worldwide trends. Increase in high-risk sexual behaviors and oral HPV infection may influence the difference in trends.
2

Sturgis, Erich M., and K. Kian Ang. "The Epidemic of HPV-Associated Oropharyngeal Cancer Is Here: Is It Time to Change Our Treatment Paradigms?" Journal of the National Comprehensive Cancer Network 9, no. 6 (June 2011): 665–73. http://dx.doi.org/10.6004/jnccn.2011.0055.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
Although relatively uncommon, oropharyngeal cancers are increasing in incidence despite declining prevalence of smoking and in direct opposition to a decreasing incidence of all other head and neck cancers. An epidemic of human papillomavirus (HPV)–associated oropharyngeal cancers seems to account for these incidence trends. Important demographic, behavioral, and prognostic characteristics define this unique population. Changes in prevention, diagnosis, evaluation, staging, and treatment are needed. This article summarizes the epidemiology and clinical behavior of HPV-associated oropharyngeal cancer and discusses evolving/potential paradigms of treatment. However, data are currently insufficient to change treatment paradigms for HPV-associated oropharyngeal cancer outside of a closely monitored clinical trial.
3

Chaturvedi, Anil K., Neal D. Freedman, and Christian C. Abnet. "The Evolving Epidemiology of Oral Cavity and Oropharyngeal Cancers." Cancer Research 82, no. 16 (August 16, 2022): 2821–23. http://dx.doi.org/10.1158/0008-5472.can-22-2124.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
In 1988, Blot and colleagues reported results from a U.S. case–control study of oral cavity or pharyngeal (oropharyngeal and hypopharyngeal) cancers, with results showing independent associations of smoking and alcohol with increased risk, multiplicative interaction effects between smoking and alcohol, and that nearly three-quarters of these cancers are attributable to smoking and alcohol. The report by Blot and colleagues represents a landmark in oropharyngeal cancer epidemiology. This study, the largest at the time, introduced several novel concepts in oropharyngeal cancer epidemiology that remain relevant today—etiologic heterogeneity, statistical interaction effects, adjusted attributable fractions, and disparities by sex and race/ethnicity. Perhaps the most significant recognition in the field since 1988 is the etiologic association of human papillomavirus (HPV, primarily HPV16) with cancers arising in the oropharynx. Today, more than 80% of oropharyngeal cancers in the United States are caused by HPV while only approximately 3% of oral cavity cancers are caused by HPV. This etiologic heterogeneity across head and cancer subsites revealed by HPV is manifest at the genetic/genomic, epidemiologic, and clinical levels. Tobacco and alcohol remain the major etiologic factors for oral cavity cancers while HPV is the major cause of oropharyngeal cancers. Thus, tobacco and alcohol control and prophylactic HPV vaccination remain the most promising prevention tools for oral cavity and oropharyngeal cancers at this time. Importantly, the ever-emerging alternative tobacco products, such as smokeless tobacco/snus, hookah and water pipes, e-cigarettes, flavored cigars and cigarillos, and oral dissolvable products, represent a key public health concern and the carcinogenic effects of these products remains an active area of investigation. See related article by Blot and colleagues, Cancer Res 1988;48:3282–7
4

Kreimer, Aimée R., Mattias Johansson, Tim Waterboer, Rudolf Kaaks, Jenny Chang-Claude, Dagmar Drogen, Anne Tjønneland, et al. "Evaluation of Human Papillomavirus Antibodies and Risk of Subsequent Head and Neck Cancer." Journal of Clinical Oncology 31, no. 21 (July 20, 2013): 2708–15. http://dx.doi.org/10.1200/jco.2012.47.2738.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
PurposeHuman papillomavirus type 16 (HPV16) infection is causing an increasing number of oropharyngeal cancers in the United States and Europe. The aim of our study was to investigate whether HPV antibodies are associated with head and neck cancer risk when measured in prediagnostic sera.MethodsWe identified 638 participants with incident head and neck cancers (patients; 180 oral cancers, 135 oropharynx cancers, and 247 hypopharynx/larynx cancers) and 300 patients with esophageal cancers as well as 1,599 comparable controls from within the European Prospective Investigation Into Cancer and Nutrition cohort. Prediagnostic plasma samples from patients (collected, on average, 6 years before diagnosis) and control participants were analyzed for antibodies against multiple proteins of HPV16 as well as HPV6, HPV11, HPV18, HPV31, HPV33, HPV45, and HPV52. Odds ratios (ORs) of cancer and 95% CIs were calculated, adjusting for potential confounders. All-cause mortality was evaluated among patients using Cox proportional hazards regression.ResultsHPV16 E6 seropositivity was present in prediagnostic samples for 34.8% of patients with oropharyngeal cancer and 0.6% of controls (OR, 274; 95% CI, 110 to 681) but was not associated with other cancer sites. The increased risk of oropharyngeal cancer among HPV16 E6 seropositive participants was independent of time between blood collection and diagnosis and was observed more than 10 years before diagnosis. The all-cause mortality ratio among patients with oropharyngeal cancer was 0.30 (95% CI, 0.13 to 0.67), for patients who were HPV16 E6 seropositive compared with seronegative.ConclusionHPV16 E6 seropositivity was present more than 10 years before diagnosis of oropharyngeal cancers.
5

Watters, Carolina, Sabrina Brar, Claire Richards, and Rafal Niziol. "Oropharyngeal cancer." InnovAiT: Education and inspiration for general practice 13, no. 11 (September 11, 2020): 650–54. http://dx.doi.org/10.1177/1755738020949569.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
The incidence of oropharyngeal cancer in the UK has almost trebled in the last few decades and continues to climb. It is expected that its associated symptoms will become increasingly common presenting complaints in primary care, where early recognition is hugely advantageous for patient outcomes. Thorough history and examination, plus a sound knowledge of associated risk factors, is vital in identifying potential cases, and an understanding of the correct referral pathways ensures patients are appropriately referred to head and neck cancer services. A broad overview of benign differential diagnoses, subsequent investigation and management of oropharyngeal cancers is helpful in order to properly inform and support patients in their next steps.
6

Liao, Cheng-I., I.-Jung Feng, Caitlin Ruth Johnson, Pin-Jie Bin, Chun-Teng Tsai, Daniel Stuart Kapp, and John K. Chan. "Human papillomavirus-associated cancers in Taiwan over the last 18 years: The potential impact of screening, vaccination, and smoking." Journal of Clinical Oncology 40, no. 16_suppl (June 1, 2022): 10574. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.10574.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
10574 Background: Human papillomavirus (HPV) is a causative agent of many human cancers. This study aims to determine the incidences and trends of HPV-associated cancers in the Republic of China. Methods: HPV-associated cancers included: cervical carcinoma, oropharyngeal squamous cell carcinoma (SCC), anal/rectal, vulvo-vaginal, and penile SCC. Deidentified data were obtained from Taiwan’s National Health Insurance Research Database from 2001 to 2018. SEER*Prep 2.6.0, SEER*Stat 8.3.9.2, and Joinpoint regression program 4.9.0.0 were used to calculate incidences and trends of HPV-associated cancers per 100,000. The age-adjusted incidence was adjusted by the WHO 2000 standard population. Results: A total of 55,248 HPV-associated cancers were identified. Of these, 34,730 (62.9%) were identified in women and 20,518 (37.1%) in men. The majority (60.0%) were cervical followed by oropharyngeal at 37.6%, and other HPV-associated cancers comprised 2.4%. Over the 18-year study, the overall age-adjusted incidence of HPV-associated cancers decreased from 13.41 to 8.92 (per/100,000) with an annual decrease of 2.02% ( P< 0.001). More specifically, cervical cancer incidence decreased from 20.42 to 7.70 per 100,000 with an annual decrease of 5.6% ( P< 0.001). Other cancers, such as vaginal and vulvar, decreased 2.34% ( P< 0.001) and 1.82% ( P< 0.001), respectively. With respect to oropharyngeal SCC, the incidence was over 12-fold higher in men compared to women (8.37 vs. 0.67/100,000) with both sexes increasing at 3.61% ( P< 0.001) and 3.59% ( P< 0.001) annually. Anal/rectal SCC increased at 3.55% ( P< 0.001) whereas penile cancer decreased at 2.52% ( P< 0.001). Of note, all HPV-associated cancers among non-smokers decreased 2.02% ( P< 0.001) annually, whereas they increased in smokers at 1.00% ( P> 0.05) per year. This increase in incidence was particularly evident in oropharyngeal SCC and cervical carcinomas. Conclusions: Women comprised over 60% of HPV related cancers, with cervical cancer being most common followed by oropharyngeal cancer. Over the last 18 years, cervical and vulvovaginal cancers decreased, but the rates of oropharyngeal cancers in men was 12-fold higher than women and continues to increase. Public awareness and education of these trends are needed toward prevention and screening.
7

Chaturvedi, Anil K., Eric A. Engels, Ruth M. Pfeiffer, Brenda Y. Hernandez, Weihong Xiao, Esther Kim, Bo Jiang, et al. "Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States." Journal of Clinical Oncology 29, no. 32 (November 10, 2011): 4294–301. http://dx.doi.org/10.1200/jco.2011.36.4596.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
Purpose Recent increases in incidence and survival of oropharyngeal cancers in the United States have been attributed to human papillomavirus (HPV) infection, but empirical evidence is lacking. Patients and Methods HPV status was determined for all 271 oropharyngeal cancers (1984-2004) collected by the three population-based cancer registries in the Surveillance, Epidemiology, and End Results (SEER) Residual Tissue Repositories Program by using polymerase chain reaction and genotyping (Inno-LiPA), HPV16 viral load, and HPV16 mRNA expression. Trends in HPV prevalence across four calendar periods were estimated by using logistic regression. Observed HPV prevalence was reweighted to all oropharyngeal cancers within the cancer registries to account for nonrandom selection and to calculate incidence trends. Survival of HPV-positive and HPV-negative patients was compared by using Kaplan-Meier and multivariable Cox regression analyses. Results HPV prevalence in oropharyngeal cancers significantly increased over calendar time regardless of HPV detection assay (P trend < .05). For example, HPV prevalence by Inno-LiPA increased from 16.3% during 1984 to 1989 to 71.7% during 2000 to 2004. Median survival was significantly longer for HPV-positive than for HPV-negative patients (131 v 20 months; log-rank P < .001; adjusted hazard ratio, 0.31; 95% CI, 0.21 to 0.46). Survival significantly increased across calendar periods for HPV-positive (P = .003) but not for HPV-negative patients (P = .18). Population-level incidence of HPV-positive oropharyngeal cancers increased by 225% (95% CI, 208% to 242%) from 1988 to 2004 (from 0.8 per 100,000 to 2.6 per 100,000), and incidence for HPV-negative cancers declined by 50% (95% CI, 47% to 53%; from 2.0 per 100,000 to 1.0 per 100,000). If recent incidence trends continue, the annual number of HPV-positive oropharyngeal cancers is expected to surpass the annual number of cervical cancers by the year 2020. Conclusion Increases in the population-level incidence and survival of oropharyngeal cancers in the United States since 1984 are caused by HPV infection.
8

Liao, Cheng-I., Michelle Ann P. Caesar, Chloe Chan, Michael Richardson, Daniel Stuart Kapp, Alex Andrea Francoeur, and John Chan. "HPV associated cancers in the United States over the last 15 years: Has screening or vaccination made any difference?" Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021): 107. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.107.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
107 Background: Human papillomavirus is a causative agent of many human cancers. This study aims to determine the incidence and trends of HPV-related cancers in the United States. Methods: HPV-associated cancers as classified by the CDC were included: oropharyngeal squamous cell carcinoma (SCC), anal & rectal SCC, vulvar SCC, vaginal SCC, cervical carcinoma, and penile SCC. Data were obtained from the United States Cancer Statistics program from 2001-2017. SEER*Stat 8.3.8 and Joinpoint regression program 4.8.0.1 were used to calculate incidence trends of HPV-associated cancers per 100,000. Results: The overall incidence of HPV related cancers for women was 13.68/100,000, more than half of which (52%) were cervical cancer, at 7.12/100,000 in the year 2017. Over the last 16 years, the incidence of cervical cancer has decreased at an annual percent change (APC) of 1.03% (p < 0.001). In contrast, oropharyngeal (APC = 0.77%, p < 0.001), anal & rectal (APC = 2.75%, p < 0.001), and vulvar SCC all increased significantly (APC = 1.27%, p < 0.001). For older women, the incidence of anal & rectal cancer approached that of cervical cancer. In those over 80, the incidence of cervical cancer was 6.95 (-2.90% APC, p < 0.001), compared to 6.36 for anal & rectal cancer (1.23% APC, p < 0.001). Using a projection model, incidence of anal & rectal cancer is expected to surpass that of cervical cancer by year 2025 for every age group over 55. For men, the incidence of all HPV-related cancers was 11.0/100,000 in the year 2017, 81% were associated with oropharyngeal cancer. Over the last 16 years, there was an overall annual increase in HPV related cancers at 2.36% per year (p < 0.001) with the highest increase in oropharyngeal (APC = 2.71%, p < 0.001) and anal & rectal SCC (APC = 1.71%, p < 0.001). Those at greatest risk of oropharyngeal cancer were older men aged 65-69 years with an incidence of 36.5/100,000 and annual percent increase of 4.24% (p < 0.001). The intersectionality of age and race showed that White men age 65-69 years had the highest incidence of oropharyngeal at 41.6/100,000. Conclusions: Overall, there was a decrease in cervical cancer incidence likely due to screening or vaccination. However, over 80% of men with HPV related cancers had oropharyngeal cancer, a nearly fivefold higher incidence compared to women. In contrast, there was a significant increase in non-screenable HPV-related cancers and anal & rectal SCC incidence is projected to surpass that of cervical cancer within 5 years for certain at-risk groups. Further resources and research should be conducted to address the lack of screening or vaccination in these preventable cancers.
9

Ahmad, A. "Oral and Oropharyngeal Cancers." CA: A Cancer Journal for Clinicians 39, no. 6 (November 1, 1989): 397. http://dx.doi.org/10.3322/canjclin.39.6.397.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Zanner, J. P. "Oral and Oropharyngeal Cancers." CA: A Cancer Journal for Clinicians 39, no. 6 (November 1, 1989): 398. http://dx.doi.org/10.3322/canjclin.39.6.398-a.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources
You might also be interested in the extended bibliographies on the topic 'Oropharyngeal Cancers' for particular source types:
Journal articles Dissertations / Theses Books

Dissertations / Theses on the topic "Oropharyngeal Cancers":

1

Oguejiofor, Kenneth Kenechukwu. "Prognostic markers in oropharyngeal cancers." Thesis, University of Manchester, 2016. https://www.research.manchester.ac.uk/portal/en/theses/prognostic-markers-in-oropharyngeal-cancers(fda96224-657d-4049-ae6c-50db33a5388a).html.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
Introduction: Human papillomavirus (HPV) is changing the prevalence, survival and treatment paradigms in oropharyngeal squamous cell carcinoma (OPSCC). Improved survival of patients with HPV positive compared to HPV negative OPSCC has led to trials of treatment de-escalation. Current HPV detection methods are imprecise, therefore standardised assessment of transcriptionally active HPV in OPSCC is required. Furthermore, the differences in immune characteristics and/or the hypoxia response/effects could explain observed differences in prognosis between HPV positive and negative OPSCC. Rigorous HPV detection and subsequent biomarker evaluation should provide additional information required before introduction of treatment de-escalation in broad patient groupings. Methods: The study cohort was 218 patients with OPSCC who received radiotherapy with curative intent. HPV status was determined on pre-treatment, formalin-fixed paraffin-embedded blocks using: 1) polymerase chain reaction (PCR); 2) in-situ hybridisation (ISH) and 3) immuno-histochemistry (IHC). QuantiGene multiplex assay was designed to detect mRNA of reference sequences of the common high-risk HPV types (16, 18, 33, 35, 45, 52 and 58). HPV detection methods were compared with mRNA quantification. Multimarker IHC of immune cell markers using chromogenic and fluorescent staining was performed, analysed and compared with single marker IHC using automated multispectral image analysis. A validated multiplex IHC method was used for a) chromogenic (CD3, CD4, CD8, and FoxP3) and b) fluorescent (CD8, CD68 and PD1/PD-L1) evaluation in tumour and stroma compartments. Single marker IHC was used to investigate tumour hypoxia markers (HIF-1α and CA-IX) in HPV positive and negative OPSCC. Results: p16 IHC and ISH were the most sensitive and specific, respectively, for classifying HPV status. The combination of the three tests had the highest positive/negative predictive values compared with QuantiGene mRNA detection. Multiplex validation showed that, for serial sections up to 6 μm apart, there were highly significant correlations (P<0.0001) between single and multiplex counts for both chromogenic and fluorescent IHC. Overall there was less variation in cell counts with fluorescent staining when compared to chromogenic staining. Multiplex IHC of TILs in HPV positive and negative OPSCC showed higher infiltration in both tumour and stromal areas of CD3+CD4+ and CD3+CD8+ T cells but not CD4+FoxP3 Tregs in HPV positive compared with HPV negative OPSCC. Only CD3+CD8+ stromal and not tumour area infiltration was associated with increased survival (P=0.02). PD-L1 expression was higher in HPV negative OPSCC and this was related to macrophage (CD68) expression of PD-L1. In HPV negative tumours infiltration with CD68+PD-L1 was associated with a good prognosis. HPV negative patients had higher expression of HIF-1α but not CA-IX. High expression of both markers was associated with a poor prognosis irrespective of HPV status. Conclusions: There are other prognostic factors operating in the larger subdivision of HPV positive and negative OPSCC. Precise HPV detection and inclusion of other prognostic factors is required before treatment de-escalation is used. Expression of immune inhibitory factors (PD1/PD-L1) alone without contextualisation with immune cell density is insufficient for patient prognostication and potential selection for therapy using immune checkpoint inhibitors. Hypoxia modification of radiotherapy should be explored in both HPV positive and negative OPSCC.
2

Siembida, Jakub. "Implications of transoral robotic surgery on the field of otolaryngology: contemporary management of oropharyngeal cancers." Thesis, Boston University, 2012. https://hdl.handle.net/2144/12627.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
Thesis (M.A.)--Boston University PLEASE NOTE: Boston University Libraries did not receive an Authorization To Manage form for this thesis or dissertation. It is therefore not openly accessible, though it may be available by request. If you are the author or principal advisor of this work and would like to request open access for it, please contact us at open-help@bu.edu. Thank you.
The incidence and prevalence of cancers of the oropharynx has been on the rise over recent years, with approximately 13,000 new cases diagnosed each year in the United States. Increased incidence has been linked to increased alcohol consumption, tobacco use, and the human papilloma virus, and stresses the importance for the development of modern treatments. The majority of oral cancers are squamous cell carcinomas, originating in the mucosal tissue layer and metastasizing throughout the neck to surrounding lymph nodes and organs. Due to the difficulty in the detection of oropharyngeal cancers, they are often detected in late stage and must be removed surgically to maximize survival. Treatment of head and neck cancers falls under the responsibility of otolaryngologists, who utilize a wide variety of surgical and non-surgical procedures to minimize morbidity and maximize the patient's chances of survival while maintaining high quality of life. The classic approach to the treatment of head and neck cancers has been a combination of neck dissection, removal of lymph nodes, and radiation therapy to obliterate the disease in its entirety. Saving the life of the patient often results in many complications as a result of the invasive and aggressive treatments. In order to maximize the removal of the cancer, collateral damage to surrounding nerves, muscles, and other essential tissues often occurs with dissection of the neck. This radical approach often leaves little regard for the future quality of life of the patient, and alternatives are being sought to address these needs. Along with other surgical fields, otolaryngology is moving toward a minimally invasive approach in the treatment of oropharyngeal cancers. With the advent of modern technology and miniaturization of instruments, minimally invasive procedures such as endoscopic surgery, laser surgery, and concentrated radio- and chemotherapeutics have allowed otolaryngologists a greater range of possible treatments for their patients. In the recent evolution of surgical treatment, robots have been developed and adapted to assist surgeons in performing difficult procedures which are otherwise not possible. Utilizing robotic arms under the control of a trained surgeon, transoral robotic surgery allows for the removal of diseased tissue via the oral cavity. This recent procedural development allows surgeons to remove cancerous lesions from the head and neck without the need for a large external incisions. This approach minimizes tissue trauma, leaving unrelated organs and tissues of the neck intact. By reducing damage to surrounding structures, transoral robotic surgery improves the prognosis of, and speeds post-surgical recovery of the patient. Transoral robotic surgery is quickly gaining traction as an acceptable alternative to open surgeries in the management of head and neck cancers, allowing for preservation of structure and function. Although promising, many variables must be considered to determine whether it is in fact the most appropriate treatment. Factors such as quality of life, the ability to swallow and speak, recovery time, comorbidity, and survival must all be taken into consideration. While transoral robotic surgery presents many benefits to the surgical team and patient, there are inevitably some drawbacks and limitations to this new and promising technology. Only recently developed and approved for the minimally invasive treatment of head and neck cancers, it presents novel and exciting possibilities to the field of otolaryngology. By analyzing the literature on surgical treatment of oropharyngeal cancers over the past twenty years, I weigh the costs and benefits of transoral robotic surgery against traditional approaches to determine what role this new procedure plays in the contemporary management of oropharyngeal cancer.
3

Auluck, Ajit. "Epidemiological shifts and risk behaviours for oral and oropharyngeal cancers in multicultural population of British Columbia, Canada." Thesis, University of British Columbia, 2012. http://hdl.handle.net/2429/41390.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
Although smoking prevalence in British Columbia (BC) is decreasing, numbers of oral cancers are increasing. This change may reflect new emerging risk factors, including an increase in human papillomavirus (HPV) infections and greater immigration from high-risk countries. Currently, in BC there is no data on the trends in oral cancer incidence and survival by ethnicity or by etiologically clustered oral cancer subsites (oral cavity cancers, OCC, which are predominantly tobacco related; and oropharyngeal cancers, OPC, which are predominantly HPV-related). Oral cancers were retrieved from BC Cancer Registry (BCCR) from 1980 to 2006 and the following information collected: names, demographic, tumor, treatment and outcome information. When specific information was not complete, chart review was done. South Asian (SA) or Chinese ethnicities were determined by using previously generated ethnic surname list. Age-adjusted incidence rates (AAIR), age-specific incidence rates (ASIR) and 5-year survival rates for these three populations were calculated by sex, grouping the cancers into etiologically clustered subsites. Calculations were done for each year from 1980 to 2006. An ethnographic study was then conducted to describe the patterns of access, use and perceptions of SA men towards chewing tobacco-containing betel quid (BQ). Extensive field work included participant observations and semi-structured interviews. We have for the first time shown that the incidence of HPV-related OPC has surpassed that of tobacco-related OCC in men. For female, the incidence rates of OPC increased and OCC unchanged. AAIR for OCC was highest in SA males and females while rates of OPC were highest in general population males and Chinese males. Survival rates for OCC were unchanged and for OPC improved in males. SA had poorest survival rates for OCC. Ethnographic findings revealed that among SA males chewing tobacco-containing BQ was viewed as a culturally accepted practice. Availability of BQ, perceived benefits of chewing, ability to conceal the habit, and a lack of awareness of health risks also supported chewing practices. These findings provide a strong foundation for continued work in this field aimed at identifying effective prevention and treatment strategies for oral cancer.
Dentistry, Faculty of
Graduate
4

Auluck, Ajit. "Epidemiological shifts and risk behaviors for oral and oropharyngeal cancers in multicultural population of British Columbia, Canada." Thesis, University of British Columbia, 2012. http://hdl.handle.net/2429/41390.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
Although smoking prevalence in British Columbia (BC) is decreasing, numbers of oral cancers are increasing. This change may reflect new emerging risk factors, including an increase in human papillomavirus (HPV) infections and greater immigration from high-risk countries. Currently, in BC there is no data on the trends in oral cancer incidence and survival by ethnicity or by etiologically clustered oral cancer subsites (oral cavity cancers, OCC, which are predominantly tobacco related; and oropharyngeal cancers, OPC, which are predominantly HPV-related). Oral cancers were retrieved from BC Cancer Registry (BCCR) from 1980 to 2006 and the following information collected: names, demographic, tumor, treatment and outcome information. When specific information was not complete, chart review was done. South Asian (SA) or Chinese ethnicities were determined by using previously generated ethnic surname list. Age-adjusted incidence rates (AAIR), age-specific incidence rates (ASIR) and 5-year survival rates for these three populations were calculated by sex, grouping the cancers into etiologically clustered subsites. Calculations were done for each year from 1980 to 2006. An ethnographic study was then conducted to describe the patterns of access, use and perceptions of SA men towards chewing tobacco-containing betel quid (BQ). Extensive field work included participant observations and semi-structured interviews. We have for the first time shown that the incidence of HPV-related OPC has surpassed that of tobacco-related OCC in men. For female, the incidence rates of OPC increased and OCC unchanged. AAIR for OCC was highest in SA males and females while rates of OPC were highest in general population males and Chinese males. Survival rates for OCC were unchanged and for OPC improved in males. SA had poorest survival rates for OCC. Ethnographic findings revealed that among SA males chewing tobacco-containing BQ was viewed as a culturally accepted practice. Availability of BQ, perceived benefits of chewing, ability to conceal the habit, and a lack of awareness of health risks also supported chewing practices. These findings provide a strong foundation for continued work in this field aimed at identifying effective prevention and treatment strategies for oral cancer.
5

Chiriseri, Edina. "Human papilloma virus and oral cancers : sexual behaviour as a risk factor." Thesis, De Montfort University, 2017. http://hdl.handle.net/2086/16084.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
AIM & OBJECTIVES: Human papilloma virus (HPV) has been related to cervical infection, however, its part in Head and Neck Squamous Cell Carcinoma (HNSCC) is still debatable and is easy to refute. Suspicion of HPV causation is heightened when carcinomas arise in patients that are young and have never smoked. The present UK based study undertaken at Northampton NHS Trust endeavoured to determine the extent to which HPV is an entity in HNSCC in the UK. Furthermore, the study investigated whether sexual behaviour (as measured by sexual health clinic (SHC) attendance) is linked the acquisition of HPV associated HNSCC in young age groups. HNSCC incidences and sexual trends in the UK were collected from publicly available databases to identify if there were any changes at a national level in sexual behaviours and their influence on HNSCC in young age groups. MATERIALS & METHODS: PCR was used to evaluate the presence of HPV in biopsy samples from of 99 patients diagnosed with HNSCC at Northampton Hospital from 2006 to 2014. Patient demographics on age, sex, smoking, alcohol use and SHC attendance were also collected. All HPV PCR positive biopsies were further genotyped using an ABI 3130xl genetic analyser. Databases in the UK; including GLOBOCAN, NATSAL and PHE were searched for data on HNSCC prevalence, sexual behaviour trends and vaccine uptake. Multinomial regression explored the relationship between HPV positivity and sex, age, smoking, drinking, race and SHC attendance. RESULTS: PCR showed that 25.2% (25/99) of biopsies tested were positive for HPV and were all obtained from white participants. Most specimens (23, 92%) were high-risk (HR) HPV 16 positive with a mean age of 56 for HPV positivity and 72% of the cases 50-60 years old. Smokers were 11% in total (11/99) with most 88.9% participants (88/99) being non-smokers. HPV positivity was strongly linked with non-smoking history (p < 0.001); no alcohol abuse (p < 0.001); male gender (p < 0.001); young age less than 60 years (p < 0.001) and SHC attendance (p < 0.001). A Kruskal-Wallis post hoc test affirmed the impact of age on HPV positivity (p= < 0.05). GLOBOCAN and Cancer Research demonstrated a rising UK HNSCC pattern of over 200% for both sexes from 1975 to 2011. The three NATSAL surveys undertaken in 1990-1991, 1999-2001 and 2010-2012 demonstrated an overall increase in opposite and same sex partners. The UK average of individuals engaging in oral sex was in the younger age groups of between 16 and 54 with at least 70% of males and 63% females of that age engaging in oral sex. Finally, NASTAL 1, 2 and 3 surveys reported 20 vs 15; 25 vs 55; 55 vs 65 of males and females respectively with more than 10 sexual partners to have attended the SHC. The UK immunization take-up was over 90% countrywide. CONCLUSION: Few research studies have been conducted to date on HPV as a cause of HNSCC in the UK. The present research showed 25.2% of HNSCC to be caused by HPV, with the high risk (HR) genotype 16 (the leading cause of cervical cancer) accounting for 92% (23/25) of the cases. These outcomes affirmed the high prevalence of HR-HPV in HNSCC, with a rate of 25.2% similar to those reported previously. Routine HPV testing in those aged below 60 is therefore warranted. Smoking and drinking showed negative correlation; the young age of below 60 and attendance of the SHC for both sexes showed a positive correlation with HPV positive HNSCC. NATSAL data showed increased sexually risky behaviour coupled with attending the SHC in younger ages for both sexes. Increased sexually risky behaviour as shown in NASTAL surveys may be the reason why young age and SHC attendance is positively correlated with HPV HNSCC. The study highlights a conceivable relationship between HPV positive HNSCC in those under 60 years with no smoking history who attended the SHC. Smoking and drinking are known risks for HNSCC in those past 65 years of age; the negative association with HPV HNSCC in the young in the present research revealed smoking and drinking to have reduced association with HPV HNSCC. The reported HR-HPV positive HNSCC in young age groups inform future vaccination strategies and consequently decrease the quantity of HPV HNSCC's.
6

Pirotte, Evelyne. "PARP inhibition in novel oropharyngeal cancer cell lines." Thesis, Cardiff University, 2017. http://orca.cf.ac.uk/109437/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
In recent decades many developed countries have seen unprecedented increases in incidence of Human Papillomavirus (HPV) associated oropharyngeal squamous cell carcinoma (OPSCC). HPV-positive OPSCC represents a new disease entity and preclinical assessment of novel therapies is hampered by a lack of relevant in vitro models. It is well-established that HPV-positive OPSCC patients generally survive longer than HPV-negative patients, and this may be partly attributable to defective repair of DNA double-strand-breaks in HPV-positive tumours. This study aimed to develop novel cell line models of HPV-OPSCC and use them, and previously validated lines, to test the hypothesis that defective DNA repair in HPV-positive cells could be exploited by synthetic lethal therapy using the Poly (ADP-ribose) polymerase (PARP) inhibitor Olaparib. Two novel HPV-positive OPSCC cell lines were derived and characterised. mRNA sequencing confirmed expression of the HPV oncogenes and HPV integration state, but did not show consistent differences in transcript levels of genes involved in DNA repair between HPV-positive and negative lines. The effects of Olaparib were assessed in a panel of eight cell lines, including effects on colony formation, cell cycle distribution, DNA double-strand-break persistence and p53 activity. All lines were sensitive to high doses of Olaparib (10 μM), however at doses between 0.5-1 μM, the surviving fractions differed significantly between lines. Two HPV-positive lines were sensitive to Olaparib (Surviving Fraction (SF) < 40%), and two were resistant (SF > 80%). Neither HPV-status, nor basal levels of PARP correlated with Olaparib sensitivity. The data were not consistent with the original hypothesis, but did suggest that monotherapy with PARP inhibitors might be useful in some OPSCC patients. The study also included an investigation into the natural history of HPV in the oropharynx. This demonstrated that HPV infection is a rare event in non-malignant tonsil tissue (prevalence of 0%: 95% confidence interval (CI) 0-0.58%).
7

Lind, Mimmi. "Recurrence detection in oropharyngeal cancer –a retrospective cohortstudy." Thesis, Örebro universitet, Institutionen för medicinska vetenskaper, 2021. http://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-93177.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
Introduction: Oropharyngeal cancer (OPC) is a highly prevalent malignancy worldwideaffecting the tonsils, the soft palette and the base of the tongue. OPC has a high risk ofrecurrence. Patients are offered a 5-year follow-up program in order to discover earlyrecurrences. However, there exists some controversy regarding the benefit of this follow-up indetecting early recurrences. Objective: The primary aim of this study was to investigate whether recurrences of OPC weredetected in patient-initiated appointments or during routine follow-up. The secondary aim wasto compare the survival between these groups. Method and materials: This study is a retrospective cohort study regarding recurrencedetection among patients diagnosed with OPC. The Örebro Head- and neck cancer registerwas used to identify patients with recurrence of OPC. Additional data was collected frommedical records. Results: A total of 75 patients were included. Routine follow-up detected 50.7% ofrecurrences while patient-initiated visits detected 42.7% of recurrences. No statisticallysignificant difference was found in survival between these groups Conclusion: In contradiction to our hypothesis most of the recurrences were detected atroutine follow-up. There was no statistically significant difference in survival between thetwo ways of detection. These results indicate that our current follow-up program has animportance in detecting early recurrences and should not be altered.
8

Ward, Matthew. "Identifying prognostic factors in oropharyngeal carcinoma." Thesis, University of Southampton, 2014. https://eprints.soton.ac.uk/376896/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Dodd, R. H. "Examining the psychosocial impact of human papillomavirus oropharyngeal cancer." Thesis, University College London (University of London), 2016. http://discovery.ucl.ac.uk/1522414/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
The causal role of human papillomavirus (HPV) in oropharyngeal squamous cell carcinoma (OSCC) has been well established. The work presented in this thesis sets out to explore the information available about HPV-OSCC and examine the psychosocial issues associated with a diagnosis of HPV-OSCC. Six studies were carried out between 2013 and 2016. Study 1 systematically reviewed the existing literature examining the psychosocial impact of HPV-OSCC in patients (n=10 studies) and current knowledge of the relationship between HPV and OSCC (n=41 studies). Study 2 was a content analysis examining the media coverage in the UK of the link between HPV and OSCC (n=112 articles). Study 3 was a qualitative study with health professionals caring for HNC patients (n=15). Study 4 was an extension of study 3, developing a survey for dissemination among health professionals working with HPV-OSCC patients (n=260). Both studies explored their experiences of and attitudes to discussing HPV with their patients, with study 4 additionally measuring knowledge of HPV-OSCC. Study 5 was a qualitative study with patients diagnosed with HPV-OSCC (n=20) and with some of these patients’ partners (n=12), examining their experiences around the diagnosis of HPV-OSCC. Study 6 involved the development of an information booklet about HPV-OSCC, based on the findings of studies 1-5. The existing literature examining the psychosocial impact of HPV-OSCC provided limited evidence about the impact of HPV in OSCC patients. Knowledge of HPV in OSCC was not well known across most populations, and the HPV-OSCC content presented in the media lacked basic facts about HPV. The increasing incidence of HPV-OSCC was a significant issue for health professionals and key messages to communicate to HPV-OSCC were found. Reactions about HPV were mixed among participants whose cancer or partners’ cancer was caused by HPV. An information booklet developed about HPV-OSCC was well received by patients and health professionals and could act as a discussion tool to provide patients with evidence-based information. De-escalation of treatment in the future may help minimise some of the negative psychosocial outcomes associated with HPV-OSCC and improve long-term functioning.
10

Houston, Karla Smalley. "The Cost of Treating Human Papillomavirus-Related Oropharyngeal Cancer." ScholarWorks, 2019. https://scholarworks.waldenu.edu/dissertations/6218.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
Human papillomavirus (HPV) is a sexually transmitted infection contributing to 70% of oropharyngeal cancers in the United States. The incidence of HPV-related oropharyngeal cancers is greater in Kentucky's population than in any other state. Research has demonstrated the cost of treating oropharyngeal cancer on a national level, but little information exists as to state-specific costs. The purpose of this quantitative study was to examine radiation therapy costs for treating HPV-related oropharyngeal cancer in Kentucky in relation to age, gender, race, and insurance. A theory by Aday and Andersen was applied to explain the relationship between the independent and dependent variables. Cluster sampling was used to randomly select 130 de-identified men and women age 40-65 years who had been diagnosed with oropharyngeal cancer. The data were collected from an existing database. The study used descriptive analysis with correlational, longitudinal data to examine the relationship of categorical and continuous variables. The mean cost for radiation therapy treatment was $123,629.14 (SD= $58,697.36). The multiple regression indicated that the null hypothesis was accepted showing that the independent variables were not statistically significant predictors of the z Score of Cost Difference [F (4,122) = 0.972, p = 0.425]. The results showed no significant independent predictor variables (p > 0.05); gender [t (127) = -0.943, p = 0.348], race [t (127) = 1.378, p = 0.171], insurance type [t (127) = -1.512, p = 0.133], and age group [t (127) = -0.230, p = 0.818]). The results may contribute to positive social change in the development of cancer prevention strategies and policies.
More sources

Books on the topic "Oropharyngeal Cancers":

1

Miller, Daniel L., and M. Sharon Stack, eds. Human Papillomavirus (HPV)-Associated Oropharyngeal Cancer. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-21100-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Zeitels, Steven M. Surgical management of tumors of the oropharynx. Alexandria, VA: American Academy of Otolaryngology--Head and Neck Surgery Foundation, 1997.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Rosenquist, Kerstin. Risk factors in oral and oropharyngeal squamous cell carcinoma: A population-based case-control study in southern Sweden. Malmö, Sweden: Department of Oral Surgery and Oral Medicine, Faculty of Odontology, Malmö University, 2005.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Hashibe, Mia, Erich M. Sturgis, Jacques Ferlay, and Deborah M. Winn. Oral Cavity, Oropharynx, Lip, and Salivary Glands. Oxford University Press, 2017. http://dx.doi.org/10.1093/oso/9780190238667.003.0029.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
Cancers of the oral cavity, oropharynx, lip, and salivary glands are malignancies of the head and neck. Some of these cancer sites share risk factors, although each has distinctive anatomic, epidemiologic, and clinical features. Oral cavity cancers arise on the inner lip and buccal mucosa, anterior two-thirds of the tongue, gum, hard palate, and floor of mouth. These cancers are strongly associated with the use of smoked and smokeless tobacco products, heavy alcohol consumption, and chewing of betel quid or pan, but only minimally associated with prior infection with human papillomavirus (HPV). In contrast, oropharyngeal cancers affect the posterior one-third (base) of the tongue, tonsils, soft palate, and other oropharyngeal tissues and are strongly associated with HPV-16 infection as well as with the use of tobacco, alcohol, and betel quid. In principle, tumors of the oral cavity, oropharynx, and lip are among the most preventable forms of cancer.
5

Oliver, Nora, and Elizabeth Chiao. Malignant Diseases in HIV. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780190493097.003.0033.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
Malignancies were one of the earliest recognized manifestations that led to the eventual description of the AIDS epidemic. Kaposi’s sarcoma was one of the first entities described in association with AIDS. Subsequently, intermediate-grade and high-grade non-Hodgkin’s lymphoma, invasive cervical cancer, and primary central nervous system lymphoma were defined by the Centers for Disease Control and Prevention as “AIDS-defining conditions.” Since the advent of combination antiretroviral therapy, several other cancers that are not AIDS-defining have been found to have an increased incidence in patients with HIV. These include, but are not limited to, Hodgkin’s disease and anal, liver, lung, oropharyngeal, colorectal, and renal cancers. They are generally referred to as “non-AIDS-defining cancers.” The increasing longevity of persons living with HIV as well as concurrent modifiable risk factors such as tobacco use may also influence the epidemiology of these malignancies.
6

Rider, Jennifer R., Paul Brennan, and Pagona Lagiou. Oral and Pharyngeal Cancer. Oxford University Press, 2018. http://dx.doi.org/10.1093/oso/9780190676827.003.0007.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
This chapter covers cancer of the oral cavity and the oropharynx, which includes the base of the tongue, soft palate, tonsils, and back and side walls of the throat. Many important risk factors for oral and oropharyngeal cancer have been identified, and in 2007 the World Health Organization determined there was sufficient evidence to include human papilloma virus (HPV) type 16 as a cause of these cancers. Tobacco and alcohol remain important modifiable risk factors, but the increasing incidence of HPV-associated tumors is now evident. While these tumors are more amenable to treatment than HPV-negative tumors, they are still a source of considerable morbidity and mortality. Moreover, the lack of a precursor lesion and limited data on efficacy of the HPV vaccine in preventing oral HPV infection are barriers to primary and secondary prevention efforts. Dietary patterns high in fruits and vegetables and low in meats may confer some protection.
7

Murphy, Barbara A., Lauren A. Zatarain, Anthony J. Cmelak, Steven Bayles, Ellie Dowling, Cheryl R. Billante, Sheila Ridner, et al. Palliative issues in the care of patients with cancer of the head and neck. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199656097.003.0145.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
Head and neck cancer (HNC) refers to tumours arising from the epithelial lining of the upper aerodigestive track, including the oral cavity, larynx, pharynx, paranasal sinuses, and salivary glands. There are 50,000 cases of HNC diagnosed annually within the United States. The majority of tumours (> 90%) are squamous cell carcinomas. Risk factors include tobacco, alcohol, and areca nuts; human papilloma virus (HPV) or Epstein-Barr virus; and mucosal irritation. Previously considered to be a disease of older adults, the epidemic of HPV-associated oropharyngeal cancers has led to a striking increase in HNC among middle-aged adults. Symptoms are usually present at the time of diagnosis and remain problematic through the terminal phase. For those patients who are cured, long-term biopsychosocial sequelae may persist for years. Thus, assessment and treatment of palliative issues is an intrinsic and vital component of care for the HNC patient.
8

P, Shah FACS Jatin, and Johnson, CMG, FMedSci MDSc, Newell W. Oral and Oropharyngeal Cancer. Taylor & Francis Group, 2018.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

P, Shah FACS Jatin, and Johnson, CMG, FMedSci MDSc, Newell W. Oral and Oropharyngeal Cancer. Taylor & Francis Group, 2018.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Shah, MD, and CMG Johnson, eds. Oral and Oropharyngeal Cancer. CRC Press, 2018. http://dx.doi.org/10.1201/9781351138543.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Oropharyngeal Cancers":

1

Gkolfinopoulos, Stavros, Panagiota Economopoulou, and Amanda Psyrri. "Prognostic Role of p16/HPV in Non-oropharyngeal Head and Neck Squamous Cell Cancer (HNSCC)." In Critical Issues in Head and Neck Oncology, 181–92. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-63234-2_12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
AbstractTranscriptionally active HPV infection is recognized as a prognostic factor in oropharyngeal squamous cell carcinoma. Also, p16 positivity has been established as an effective surrogate biomarker for HPV and shares its prognostic significance in cancer of the oropharynx. Less clear is the prognostic role of p16/HPV status in non-oropharyngeal head and neck cancers since relevant studies have produced conflicting results. The existing evidence suggests that p16 is a poor surrogate marker for HPV infection in non-oropharyngeal cancers, while the prognostic impact of HPV positivity is reserved for the oropharynx. Consequently, routine HPV testing is not recommended for disease sites of the head and neck outside oropharynx.
2

Murthy, Samskruthi P., Krishnakumar Thankappan, and Subramania Iyer. "Dysphagia After Oropharyngeal Surgery." In Dysphagia Management in Head and Neck Cancers, 241–55. Singapore: Springer Singapore, 2018. http://dx.doi.org/10.1007/978-981-10-8282-5_21.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Warnakulasuriya, Saman, and John S. Greenspan. "Epidemiology of Oral and Oropharyngeal Cancers." In Textbook of Oral Cancer, 5–21. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-32316-5_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Warnakulasuriya, Saman, Hatsuhiko Maeda, and John S. Greenspan. "Pathology of Oral and Oropharyngeal Cancers." In Textbook of Oral Cancer, 69–80. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-32316-5_7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Dahlstrom, Kristina R., and Erich M. Sturgis. "Other HPV-Associated Cancers (Oropharyngeal and Penile)." In Encyclopedia of AIDS, 1–7. New York, NY: Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4614-9610-6_18-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Dahlstrom, Kristina R., and Erich M. Sturgis. "Other HPV-Associated Cancers (Oropharyngeal and Penile)." In Cancers in People with HIV and AIDS, 289–97. New York, NY: Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4939-0859-2_21.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Dahlstrom, Kristina R., and Erich M. Sturgis. "Other HPV-Associated Cancers (Oropharyngeal and Penile)." In Encyclopedia of AIDS, 1603–9. New York, NY: Springer New York, 2018. http://dx.doi.org/10.1007/978-1-4939-7101-5_18.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Posner, Marshall R. "Clinical Management of HPV-Related Oropharyngeal Cancer." In HPV and Head and Neck Cancers, 87–97. New Delhi: Springer India, 2015. http://dx.doi.org/10.1007/978-81-322-2413-6_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Wollenberg, Barbara. "Immunotherapy-Based Approaches for Treatment of Oral and Oropharyngeal Cancers." In Textbook of Oral Cancer, 387–97. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-32316-5_28.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Campisi, Giuseppina, and Vera Panzarella. "Human Papillomavirus Infection: A Risk Factor for Oral and Oropharyngeal Cancers." In Textbook of Oral Cancer, 31–45. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-32316-5_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Oropharyngeal Cancers":

1

Kim, Min Hwan, Jae-Hwan Kim, Dong Min Jung, Jae Woo Choi, Soo Jin Heo, Kyoung-Ho Pyo, Min Hee Hong, Byoung Chul Cho, and Hye Ryun Kim. "Abstract 4946: Comprehensive molecular profiling reveals distinct immunemicroenvironment subtypes of oropharyngeal cancers." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-4946.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Kim, Min Hwan, Jae-Hwan Kim, Dong Min Jung, Jae Woo Choi, Soo Jin Heo, Kyoung-Ho Pyo, Min Hee Hong, Byoung Chul Cho, and Hye Ryun Kim. "Abstract 4946: Comprehensive molecular profiling reveals distinct immunemicroenvironment subtypes of oropharyngeal cancers." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-4946.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Wang, Vivian W., Rebecca R. Laborde, Yan W. Asmann, Yang Li, Jian Ma, Bruce W. Eckloff, Nicole M. Tombers, et al. "Abstract 3100: Identifying novel chromosomal fusions out of RNAseq data from oropharyngeal cancers." In Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-3100.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Smith, David I., Rebecca Laborde, Vivian Wang, Alexandria Greenberg, Nicole Tombers, Bruce Eckloff, Eric Moore, and Olsen Kerry. "Abstract 3885: Inactivation of expression of many extremely large genes in oropharyngeal cancers." In Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-3885.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Lim, Yenkai, Naoki Fukuma, Makrina Totsika, Liz Kenny, Mark Morrison, and Chamindie Punyadeera. "Abstract 577: Oral microbiome biomarker panel to detect oral and oropharyngeal cancers in a clinical setting." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-577.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Rosado, Paola M., Filipa Godoy-Vitorino, Jose A. Vivaldi, Ana P. Ortiz, Jeslie M. Ramos-Cartagena, and Cynthia M. Pérez. "Abstract C025: Lifestyle risk factors for oral and oropharyngeal cancers in patients attending sexually transmitted infection clinics in Puerto Rico." In Abstracts: Twelfth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; September 20-23, 2019; San Francisco, CA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7755.disp19-c025.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Bolyos, Anthony, and Pinaki Bose. "Abstract A07: Improved prognosis of HPV-positive oropharyngeal cancers is associated with a suppression of TGF-β-mediated immune evasion." In Abstracts: AACR-AHNS Head and Neck Cancer Conference: Optimizing Survival and Quality of Life through Basic, Clinical, and Translational Research; April 29-30, 2019; Austin, TX. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1557-3265.aacrahns19-a07.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Lubpairee, Tarinee, Yi-Ping Liu, John Hay, Tom Thomson, and Catherine Fang Poh. "Abstract LB-445: Human papillomavirus (HPV) status is a long-term survival indicator for patients with oropharyngeal cancers in British Columbia." In Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-lb-445.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Künzel, J., Anna Katharina Beltz, S. Zimmer, and RH Stauber. "Extracapsular growth in HPV positive oropharyngeal cancer." In Abstract- und Posterband – 91. Jahresversammlung der Deutschen Gesellschaft für HNO-Heilkunde, Kopf- und Hals-Chirurgie e.V., Bonn – Welche Qualität macht den Unterschied. © Georg Thieme Verlag KG, 2020. http://dx.doi.org/10.1055/s-0040-1711029.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Hoffmann, F., T. Krüger, O. Guntinas-Lichius, F. Eggeling, O. Kniemeyer, and G. Ernst. "Molecular cartography of Oropharyngeal Cancer using MALDI Imaging." In Abstract- und Posterband – 89. Jahresversammlung der Deutschen Gesellschaft für HNO-Heilkunde, Kopf- und Hals-Chirurgie e.V., Bonn – Forschung heute – Zukunft morgen. Georg Thieme Verlag KG, 2018. http://dx.doi.org/10.1055/s-0038-1639830.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Oropharyngeal Cancers":

1

Zhang, Dongyuan, Ling Zhang, Xuchao Zhu, Jingwen Li, and Chuan Qin. Prognostic role of neutrophil-To-Lymphocyte ratio in oropharyngeal cancer: A systematic review and meta-analysis including 6,987 patients. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, September 2020. http://dx.doi.org/10.37766/inplasy2020.9.0032.

Full text
APA, Harvard, Vancouver, ISO, and other styles

To the bibliography